Ascentage Pharma Group International (AAPG) — 6-K Filings

All 6-K filings from Ascentage Pharma Group International. Browse 43 Foreign Current Report reports with AI-powered summaries and risk analysis.

6-K Filings (43)

6-K Filing — Apr 1, 2026
ASCENTAGE PHARMA Files 6-K with Press Release, HKEX Announce — Mar 26, 2026
ASCENTAGE PHARMA GROUP INTERNATIONAL filed a 6-K on March 26, 2026, including a press release and a Hong Kong Stock Exchange announcement, both dated March 25,
Ascentage Pharma Announces Board and Committee Changes — Dec 31, 2025 Risk: low
On December 30, 2025, Ascentage Pharma Group International announced changes to its board and committees. These include a change in the composition of the Nomin
Ascentage Pharma to Present at J.P. Morgan Healthcare Conference — Dec 17, 2025 Risk: low
Ascentage Pharma Group International announced on December 17, 2025, that it will present at the 44th Annual J.P. Morgan Healthcare Conference. The company, loc
6-K Filing — Dec 9, 2025
Ascentage Pharma Presents Lisaftoclax Data at ASH Meeting — Dec 8, 2025 Risk: low
Ascentage Pharma Group International announced on December 6, 2025, that it presented pivotal China registrational study data for its drug Lisaftoclax at the 20
6-K Filing — Dec 5, 2025
6-K Filing — Dec 1, 2025
Ascentage Pharma Grants RSUs and Share Options — Nov 28, 2025 Risk: low
Ascentage Pharma Group International announced on November 27, 2025, that it has made further grants of Restricted Stock Units (RSUs) under its 2022 RSU Scheme
Ascentage Pharma GIST Drug Data Published in Nature — Nov 25, 2025 Risk: low
Ascentage Pharma Group International announced on November 24, 2025, that its Phase Ib study results for olverembatinib in gastrointestinal stromal tumors (GIST
Ascentage Pharma to Attend 3 Investor Conferences in December — Nov 19, 2025 Risk: low
Ascentage Pharma Group International announced on November 19, 2025, that it will participate in three investor conferences in December 2025. The company, locat
Ascentage Pharma to Present Olverembatinib Data at ASH 2025 — Nov 4, 2025 Risk: medium
Ascentage Pharma Group International announced on November 3, 2025, that it will present data from multiple studies of its drug Olverembatinib at the ASH 2025 c
Ascentage Pharma to Present at Investor Conferences — Oct 30, 2025 Risk: low
Ascentage Pharma Group International announced on October 29, 2025, that it will participate in two investor conferences in November 2025. The company, located
Ascentage Pharma to Attend 3 Investor Conferences in October — Oct 7, 2025 Risk: low
Ascentage Pharma Group International announced on October 7, 2025, that it will participate in three investor conferences during October 2025. The company, loca
Ascentage Pharma to Attend 3 Investor Conferences in September — Aug 28, 2025 Risk: low
Ascentage Pharma Group International announced on August 25, 2025, that it will participate in three investor conferences in September 2025. The company, locate
Ascentage Pharma Reports 2025 Interim Financials — Aug 21, 2025 Risk: low
Ascentage Pharma Group International reported its unaudited six-month financial results for the interim period ending August 20, 2025. The company, based in Suz
Ascentage Pharma's Lisaftoclax Trial Cleared by FDA & EMA — Aug 18, 2025 Risk: medium
Ascentage Pharma Group International announced on August 17, 2025, that the US FDA and EMA have cleared their global registrational Phase III trial for lisaftoc
Ascentage Pharma Announces Board Meeting — Aug 8, 2025 Risk: low
Ascentage Pharma Group International announced on August 8, 2025, that its Board of Directors will hold a meeting. The purpose of the meeting is not specified i
Ascentage Pharma to Announce H1 2025 Results Aug 20 — Aug 7, 2025 Risk: low
Ascentage Pharma Group International announced on August 7, 2025, that they will report their 2025 six-month interim results and provide a corporate update on A
Ascentage Pharma to Present at Evercore China Biotech Summit — Aug 1, 2025 Risk: low
Ascentage Pharma Group International announced on August 1, 2025, that it will participate in the Evercore China Biotech Summit. The company, headquartered in S
Ascentage Pharma Closes Share Placing and Subscription — Jul 25, 2025 Risk: low
On July 25, 2025, Ascentage Pharma Group International announced the closing of a placing of existing shares and a top-up subscription of new shares under a gen
Ascentage Pharma Closes Share Placement — Jul 17, 2025 Risk: low
Ascentage Pharma Group International announced the closing of its top-up placement of shares on July 17, 2025. The company, based in Suzhou, China, filed a Form
Ascentage Pharma Enters Placing and Subscription Agreement — Jul 15, 2025 Risk: medium
On July 14, 2025, Ascentage Pharma Group International entered into a Placing and Subscription Agreement with The Dajun Yang Dynasty Trust, J.P. Morgan Securiti
Ascentage Pharma's Lisaftoclax Approved in China for CLL/SLL — Jul 10, 2025 Risk: medium
On July 10, 2025, Ascentage Pharma Group International announced that its novel Bcl-2 inhibitor, lisaftoclax, received approval from the China National Medical
Ascentage Pharma Names New CFO and SVP — Jul 8, 2025 Risk: low
Ascentage Pharma Group International announced on July 7, 2025, the appointment of Dr. Veet Misra as its new Chief Financial Officer and Eric Huang as Senior Vi
Ascentage Pharma Grants More RSUs — Jun 27, 2025 Risk: low
On June 27, 2025, Ascentage Pharma Group International announced the further grant of awards under its 2021 and 2022 Restricted Stock Unit (RSU) Schemes. This a
Ascentage Pharma Presents Olverembatinib Data at EHA 2025 — Jun 16, 2025 Risk: medium
On June 15, 2025, Ascentage Pharma Group International announced encouraging data from multiple studies of olverembatinib in Ph+ ALL at EHA 2025. The company al
Ascentage Pharma Assets to be Presented at EHA Congress — Jun 10, 2025 Risk: low
Ascentage Pharma Group International announced on June 9, 2025, that thirteen of its drug candidates, including olverembatinib and lisafoclax, have been selecte
Ascentage Pharma Presents Promising Alrizomadlin Data at ASCO 2025 — Jun 3, 2025 Risk: medium
Ascentage Pharma Group International announced promising clinical data on its drug alrizomadlin, both as a monotherapy and in combination treatments, for solid
Ascentage Pharma's Lisaftoclax Shows Promise at ASCO 2025 — May 23, 2025 Risk: medium
Ascentage Pharma Group International announced on May 22, 2025, that clinical data for their drug lisaftoclax demonstrated therapeutic potential in patients who
Ascentage Pharma Reports AGM Poll Results — May 20, 2025 Risk: low
Ascentage Pharma Group International filed a Form 6-K on May 20, 2025, reporting the poll results from their Annual General Meeting held on May 19, 2025. The an
Ascentage Pharma Presents Preclinical Cancer Study Results — Apr 28, 2025 Risk: low
Ascentage Pharma Group International announced on April 28, 2025, that it presented results from five preclinical studies at the 2025 American Association of Ca
Ascentage Pharma drugs in CSCO 2025 Guidelines — Apr 21, 2025 Risk: low
On April 21, 2025, Ascentage Pharma Group International announced that its drugs, lisafoclax and olverembatinib, have been included in the Chinese Society of Cl
Ascentage Pharma Files 2024 Annual Report — Apr 17, 2025 Risk: low
Ascentage Pharma Group International filed its annual report on Form 20-F for the fiscal year ended December 31, 2024, on April 16, 2025. The company, located a
Ascentage Pharma: Trustee Buys Shares for RSU Scheme — Apr 8, 2025 Risk: low
On April 8, 2025, Ascentage Pharma Group International announced a voluntary disclosure regarding the purchase of shares by the trustee for its 2022 Restricted
Ascentage Pharma Trustee Buys Shares for RSU Scheme — Mar 31, 2025 Risk: low
On March 31, 2025, Ascentage Pharma Group International announced a share purchase by its trustee for the purpose of its 2022 Restricted Stock Unit (RSU) Scheme
Ascentage Pharma Files 6-K for March 2025 — Mar 27, 2025 Risk: low
Ascentage Pharma Group International filed a Form 6-K on March 27, 2025, reporting information for the month of March 2025. The filing is from their principal e
Ascentage Pharma to Present Pipeline Data at AACR 2025 — Mar 26, 2025 Risk: low
Ascentage Pharma Group International announced on March 25, 2025, that it will present five preclinical studies from its pipeline at the American Association of
Ascentage Pharma Files 6-K for March 2025 — Mar 12, 2025 Risk: low
Ascentage Pharma Group International filed a Form 6-K on March 12, 2025. This report is for the month of March 2025 and indicates the company is a foreign priva
Ascentage Pharma Files Routine 6-K Report — Mar 6, 2025 Risk: low
Ascentage Pharma Group International filed a Form 6-K on March 6, 2025, reporting for the month of March 2025. The company is a foreign private issuer based in
Ascentage Pharma Changes Company Secretary — Feb 25, 2025 Risk: low
On February 25, 2025, Ascentage Pharma Group International announced a change in its Company Secretary and Authorized Representative. This update was formally c
Ascentage Pharma Partially Exercises ADS Over-Allotment Option — Feb 14, 2025 Risk: low
Ascentage Pharma Group International announced the partial exercise of the over-allotment option related to its American Depositary Shares (ADS) offering on Feb
Ascentage Pharma Partially Exercises ADS Over-Allotment Option — Feb 11, 2025 Risk: low
Ascentage Pharma Group International announced on February 7, 2025, the partial exercise of the over-allotment option for its American Depositary Shares (ADS) o

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX